MetaCap

Greenwich LifeSciences Inc. (GLSI)

NASDAQ: GLSIHealth CareBiotechnology: Pharmaceutical PreparationsUSD

19.25-0.54 (-2.73%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

GLSI stock chart

Technical analysis

Key statistics

All statistics
Market cap
$282.56M
EPS (TTM)
-$1.63
52-week range
7.78 – 34.10
Day range
18.40 – 20.20
Volume / Avg
472.11K / 160.76K
Beta
—

52-week range

$7.78$34.10

GLSI stock today

Greenwich LifeSciences (GLSI) closed at $19.25 on Nov 20, down 2.73% (-$0.54), versus the S&P 500's 3.70% decline. Volume was 2.9x the average at 472.11K shares, a sign of unusually heavy trading. Shares are 43.5% below their 52-week high of $34.10, set on Jan 27, 2026 and 147.4% above the 52-week low of $7.78, in the middle of the past year's range.

GLSI is down 8.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 136.2%. Greenwich LifeSciences has posted a net loss over the last twelve months (EPS of -$1.63), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Greenwich LifeSciences

Company profile

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Snehal S. Patel
Headquarters
Stafford, TX
IPO year
2020

Financial highlights

Full financials

Greenwich LifeSciences reported a net loss of $19.4 million, compared with a loss of $17.4 million a year earlier. Diluted earnings per share came in at -$1.43.

Greenwich LifeSciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-19.36M$-17.41M$-8.89M$-7.83M$-4.57M
EPS (diluted)$-1.43$-1.34$-0.69$-0.61$-0.35

Analyst forecast

Forecast

Consensus (2 analysts)

strong_buy

Avg. price target

$57.50+198.70%

  • Strong buy 0
  • Buy 2
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $45.00High $70.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-0.30 vs $-0.30

GLSI news

All GLSI news

Greenwich LifeSciences peers

Health Care sector
GLSI peer companies
CompanyPrice% ChgMarket capCompare
FULCFulcrum Therapeutics Inc.3.69-0.54%$281.85Mvs GLSI
RLMDRelmada Therapeutics Inc.2.62-15.76%$279.54Mvs GLSI
BNTCBenitec Biopharma Inc.7.92-2.76%$285.88Mvs GLSI
EVMNEvommune Inc.7.04-2.76%$291.10Mvs GLSI
GALTGalectin Therapeutics Inc.2.69-4.27%$271.35Mvs GLSI
SPRYARS Pharmaceuticals Inc.2.96-11.90%$297.56Mvs GLSI
VCREVicore Pharma Holding AB ADR9.41-5.09%$264.89Mvs GLSI
EBSEmergent BioSolutions Inc.5.05-1.94%$259.65Mvs GLSI

Indexes, lists and sector

Greenwich LifeSciences stock FAQ

What is Greenwich LifeSciences's stock price today?

GLSI last traded at $19.25 as of Nov 20, 4:00 PM EST, down 2.73% on the day. Prices are delayed at least 15 minutes.

Who is Greenwich LifeSciences's CEO?

Mr. Snehal S. Patel is the chief executive officer of Greenwich LifeSciences Inc..

What is the GLSI 52-week high?

The 52-week high for GLSI is $34.10 and the 52-week low is $7.78. The stock is currently 43.5% below its high.

Compare GLSI